Attorney Docket No. Le A 36 784

## IAPS RECEIVED 03 DEC 2005,

**PATENT** 

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Martin HENDRIX, et al.

Serial No.: [to be assigned] - National Stage Filing of PCT/EP2004/006477

Title: 6-Arylamino-5-Cyano-4-Pyrimidinones as PDE9A Inhibitors

MAIL STOP PCT COMMISSIONER FOR PATENTS P.O. BOX 1450 ALEXANDRIA, VA 22313-1450

# TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT WITHIN THREE MONTHS OF DATE OF NATIONAL STAGE ENTRY 37 C.F.R. 1.97(b)(2)

Dear Sir:

Applicants wish to cite for the record in the above-identified application the references shown on the accompanying form(s) PTO/SB/08A-B [substitute for form 1449/PTO]. A copy of the International Search Report is also enclosed for your reference.

## IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING INFORMATION DISCLOSURE STATEMENT

The information disclosure statement transmitted herewith is being filed concurrently with the request under 35 U.S.C. § 371(f) to begin national examination procedures.

#### **FEE PAYMENT**

Applicants believe that no fees are due with this submission. However, the Commissioner is hereby authorized to charge any fees that may have been overlooked but that are required to Deposit Account 13-3372. Additionally, please credit any overpayment to the same account.

Respectfully submitted,

Susan M. Helleguie Susan M. Pellegrino Reg. No.: 48,972

Attorney for Applicant(s)

Bayer Pharmaceuticals Corporation 400 Morgan Lane West Haven, CT 06516

Telephone: (203) 812-6450 Facsimile: (203) 812-6459

### MPonecurciveto 06 21.0 2005

PTO/SB/08A (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

#### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known					
Application Number	[to be a stigned], 5995 A				
Filing Date					
First Named Inventor	Martin HENDRIX				
Art Unit					
Examiner Name					
Attorney Docket Number	Ι Δ Δ 36 784				

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevan Figures Appear
	<u> </u>	US-			
		US-			
	<del> </del> -	US-			
		US-			
	-	US-			
		US-	1		
		US-			····
		US-			
		US-			
		US-			
	1	US-			
		US-			
		US-			
		US-			

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T <sup>6</sup>
	F1	EP 0 130 735 A1	01/09/1985	American Home Produ	cts Corporation	
	F2	WO 98/10765 A1	03/19/1998	Leland Stanford Junior	University	
	F3	WO 03/037899 A1	05/08/2003	Pfizer Limited and Pfiz	er Inc.	
						igspace
	<u> </u>					<b>_</b>
			1 1			

Examiner	Date	е		
Signature	Cons	sidered		
_		,	ĺ	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at <a href="www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language

the appropriate symbols as indicated on the document under WIPO Standard S1.16 if possible. Applicant is to place a creek mark neight a English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND

To: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

\*\*Translation\*\*

\*\*Translat

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

## IAP8 Rec'd PCT/PTO 08 DEC 2005

PTO/SB/08B (07-05)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	e for form 1449/PTO			re required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
2233.210.01.01.01.01.00				Application Number	[to be assigned]	
INFO	DRMATION	N DIS	CLOSURE	Filing Date		
STA	TEMENT I	BY A	PPLICANT	First Named Inventor	Martin HENDRIX	
	// los as many ab			Art Unit		
	(Use as many sh	eeis as n	ecessary)	Examiner Name		
Sheet	2	of	2	Attorney Docket Number	Le A 36 784	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>				
	R1	Bagli, J., et al., "Chemistry and Positive Inotropic Effect of Pelrinone and Related Derivatives. A Novel Class of 2-Methylpyridinones as Inotropic Agents", J. Med. Chem., 31(4): 814-823 (1988)			

Signature	Considered	
Examiner	Date	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.